HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Etoposide combination therapy for small cell carcinoma of the lung.

Abstract
Sixty-three consecutive patients with small cell carcinoma of the lung were treated by six cycles at 3-week intervals of etoposide 120 mg/m2 i.v. on day 1 and orally on days 2-5, adriamycin 40 mg/m2 i.v. on day 1 and vincristine 1.4 mg/m2 i.v. on day 1. Tumour bed irradiation was administered to patients with limited disease after chemotherapy. In limited-disease and extensive-disease patients the median survival was 12 and 6 months respectively. The 2-year survival rate (life table) in limited-disease patients was 26%. Treatment morbidity was low. A prospective randomised trial is being undertaken to further evaluate the role of oral etoposide in combination chemotherapy.
AuthorsR P Abratt, P A Willcox, R H Hewitson
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 20 Issue 1 Pg. 83-4 ( 1987) ISSN: 0344-5704 [Print] Germany
PMID3040288 (Publication Type: Journal Article)
Chemical References
  • Vincristine
  • Etoposide
  • Doxorubicin
Topics
  • Adult
  • Aged
  • Carcinoma, Small Cell (drug therapy, radiotherapy)
  • Doxorubicin (therapeutic use)
  • Drug Administration Schedule
  • Etoposide (therapeutic use)
  • Female
  • Humans
  • Lung Neoplasms (drug therapy, radiotherapy)
  • Male
  • Middle Aged
  • Vincristine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: